You are here: Industry Insights > Esketamine

News List

Janssen’s esketamine nasal spray approved in the EU pharmaceutical-technology
December 24, 2019
The European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray for treatment-resistant major depressive disorder.
Esketamine Nasal Spray May Improve Refractory Depression Outcomes drugs
June 03, 2019
Esketamine Nasal Spray May Improve Refractory Depression Outcomes.
ICER’s Evidence Report Finds Esketamine May Benefit Patients with Treatment-Resistant Depression but Exceeds Cost-Effectiveness Thresholds firstwordpharma
May 10, 2019
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of esketamine (Spravato™, Janssen) ...
FDA panel supports Janssen’s esketamine nasal spray for depression pharmaceutical-technology
February 14, 2019
Janssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its esketamine nasal spray Spravato to treat adults with treatment-resistant depression.
Janssen Announces Mixed Results of Esketamine Nasal Spray Study americanpharmaceuticalreview
September 25, 2018
Janssen Pharmaceutical announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression.
Johnson & Johnson preps for esketamine filing in resistant depression, despite a missed trial fiercebiotech
May 08, 2018
A new type of drug for depression has been a long time coming, and Johnson & Johnson is looking increasingly likely to end the drought with esketamine—even though one of its late-stage trials missed the mark.
Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality biospace
April 17, 2018
Johnson & Johnson Jansen pharmaceutical company announced today, from a concept of a concept of ketamine nasal spray in the clinical study phase 2, published in the American Journal of psychiatry.